Oxaliplatin Deltapharma

Oxaliplatin, the active ingredient in Oxaliplatin Deltapharma, is a platinum-based chemotherapy presented as a sterile powder for intravenous infusion use. It treats colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Deltapharma as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Deltapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin Deltapharma is a platinum‑based agent used in the treatment of cancers that arise from the gastrointestinal tract.

- Colorectal cancer: improves the overall response and disease‑control rates when combined with fluoropyrimidine‑based regimens. - Gastric cancer: used in combination chemotherapy protocols to enhance tumor shrinkage. - Pancreatic cancer: added to multi‑drug regimens to increase progression‑free survival. - Esophageal cancer: contributes to tumor response in multimodal treatment plans. - Peritoneal carcinomatosis: employed as part of hyper‑hyper‑hyper HI‑HI regional therapy approaches. - Metastatic adenoc t  t  t  t  t.

Oxaliplatin may elicit a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during or after infusion. - Peripheral neuropathy: tingling or numbness in the hands and feet, often dose‑related. - Diarrhea: watery stools that may require supportive care. - Fatigue: generalized tiredness experienced during treatment cycles. - Thrombocytopenia: reduced platelet count observed in blood tests. - Elevated liver enzymes: mild increases in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical intervention. - Acute hemolytic anemia: rapid destruction of red blood cells. - Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnea. - Renal impairment: decreased kidney function noted in laboratory monitoring. - Cardiac arrhythmias: irregular heart rhythms observed during infusion. - Secondary malignancies: rare development of new cancers after prolonged exposure.

When using Oxaliplatin Deltapharma, clinicians should follow established safety protocols and monitor patients closely.

- Pre‑infusion assessment: evaluate renal, hepatic and hematologic function before each dose. - Hydration: ensure adequate intravenous fluids to reduce nephrotoxicity risk. - Neuropathy monitoring: assess sensory changes regularly and adjust dosing if needed. - Pregnancy and lactation: avoid use; discuss risks with patients of child‑bearing potential. - Drug interactions: review concomitant medications for potential additive toxicities. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Oxaliplatin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney damage. - Anticoagulants (e.g., warfarin): heightened bleeding risk due to thrombocytopenia. - High‑dose vitamin C: may reduce platinum‑DNA binding effectiveness.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may require dose adjustment for optimal control of nausea. - CYP450 inducers (e.g., rifampicin): potential impact on drug clearance. - Immunosuppressants (e.g., cyclosporine): monitor for enhanced myelosuppression.